Tivozanib is a VEGF-inhibitor that has been extensively studied in the context of solid tumors and in advanced RCC through preclinical data and clinical trials but has only recently (late 2017) been approved as therapy for mRCC patients [24, 25]. The gene discussed is VEGFA; the disease is renal cell carcinoma.